In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Susana Banerjee to discuss SOLO1. Dr. Banerjee is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit. She is also Reader in Women’s Cancers at the Institute of Cancer Research. Dr Banerjee specialises in ovarian cancer and the systemic treatment of endometrial and cervical cancers.



Highlights:
- This report is the longest follow-up period for a PARP inhibitor in the newly diagnosed advanced ovarian cancer.
- The present analysis shows a PFS benefit that is sustained for several years following completion of 2 years of maintenance olaparib.
- PFS benefit was consistent irrespective of higher or lower clinical risk or BRCA1 or BRCA2 mutation.
- SOLO1 is the first to report longer-term follow-up for safety in patients with newly diagnosed ovarian cancer receiving a PARPi as maintenance treatment.
- The safety profile for patients in the maintenance olaparib remained consistent with that reported previously, with no new safety signals. Importantly, no additional cases of MDS or AML were reported.